Stratos Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Stratos Wealth Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$357K	Sell	97,161 -2,733	-3%	-$9.1K	﹤0.01%	1311
2026 Q1	$307K	Sell	99,894 -16,540	-14%	-$63.9K	﹤0.01%	1306
2025 Q4	$476K	Buy	116,434 +5,823	+5%	+$28.8K	0.01%	1066
2025 Q3	$540K	Buy	110,611 +11,907	+12%	+$62.5K	0.01%	983
2025 Q2	$499K	Buy	98,704 +86,730	+724%	+$426K	0.01%	927
2025 Q1	$63.3K	Sell	11,974 -4,579	-28%	-$33.4K	﹤0.01%	1333
2024 Q4	$112K	Buy	+16,553	New	+$111K	﹤0.01%	1395
2024 Q2	–	Sell	-13,436	Closed	-$134K	–	1437
2024 Q1	$134K	Buy	+13,436	New	+$150K	﹤0.01%	1324

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Stratos Wealth Partners's RXRX Position: Q2 2026 in Review

Stratos Wealth Partners reduced its Recursion Pharmaceuticals (RXRX) stake by 2.7% in Q2 2026, selling an estimated $9.1K and leaving 97,161 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

Stratos Wealth Partners first reported a position in RXRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $540K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Stratos Wealth Partners held 97,161 shares of Recursion Pharmaceuticals worth $357K as of Q2 2026.
Stratos Wealth Partners sold 2,733 Recursion Pharmaceuticals shares in Q2 2026, an estimated $9.1K.
Recursion Pharmaceuticals made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1311 holding.
Stratos Wealth Partners first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
Stratos Wealth Partners's Recursion Pharmaceuticals position peaked at $540K in Q3 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.